Athenex Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Athenex sono diminuiti a un tasso medio annuo di -7.6%, mentre il settore Biotechs ha visto gli utili crescere a un tasso medio annuo di 19.1%. I ricavi sono cresciuti crescere a un tasso medio annuo di 11.2%.

Informazioni chiave

-7.6%

Tasso di crescita degli utili

9.2%

Tasso di crescita dell'EPS

Biotechs Crescita del settore	17.0%
Tasso di crescita dei ricavi	11.2%
Rendimento del capitale proprio	n/a
Margine netto	-95.3%
Ultimo aggiornamento sui guadagni	31 Dec 2022

Aggiornamenti sulle prestazioni recenti

Recent updates

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts

Mar 06

Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?

Feb 19

When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

Jan 29

Ripartizione dei ricavi e delle spese

Come Athenex guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

OTCPK:ATNX.Q Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A	Spese di R&S
31 Dec 22	103	-98	49	52
30 Sep 22	123	-178	70	56
30 Jun 22	121	-192	71	65
31 Mar 22	109	-198	67	71
31 Dec 21	95	-158	57	78
30 Sep 21	113	-132	75	78
30 Jun 21	117	-135	83	79
31 Mar 21	137	-144	86	80
31 Dec 20	144	-142	93	76
30 Sep 20	157	-118	84	79
30 Jun 20	141	-116	78	80
31 Mar 20	123	-108	77	101
31 Dec 19	101	-123	66	84
30 Sep 19	88	-129	60	65
30 Jun 19	87	-141	55	46
31 Mar 19	77	-145	51	3
31 Dec 18	89	-117	49	120
30 Sep 18	83	-119	50	0
30 Jun 18	78	-96	49	0
31 Mar 18	71	-97	49	0
31 Dec 17	38	-131	46	2
30 Sep 17	28	-143	44	0
30 Jun 17	20	-144	40	0
31 Mar 17	21	-118	31	0
31 Dec 16	21	-88	26	0
30 Sep 16	21	-61	21	0
31 Dec 15	14	-51	26	0
31 Dec 14	1	-18	5	2

Guadagni di qualità: ATNX.Q al momento non è redditizia.

Margine di profitto in crescita: ATNX.Q al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: ATNX.Q non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 7.6% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di ATNX.Q nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: ATNX.Q non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Biotechs ( 16.6% ).

Rendimento del capitale proprio

ROE elevato: Le passività di ATNX.Q superano le sue attività, quindi è difficile calcolare il suo rendimento del capitale proprio.

Athenex Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Recent updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Motion for Asset Sale Filed by Athenex, Inc.

Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)

Athenex Announces Reverse Stock Split

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Price target decreased to US$2.17

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.

Athenex prices $30M in stock and warrants offering

Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex

Athenex surges 70% as Dr Reddy's and Intas race to form buyout deal

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex GAAP EPS, revenue misses estimates

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million.

Athenex to sell its China API business for $19M

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target decreased to US$4.50

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Price target decreased to US$4.50

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$5.50

Price target increased to US$6.67

Athenex Announces Appoints Joe Annoni as Chief Financial Officer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021

Independent Director recently bought US$61k worth of stock

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)

Independent Director recently bought US$161k worth of stock

Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.

Chief Financial Officer Randoll Sze has left the company

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)

Consensus EPS estimates fall to -US$1.31

Price target decreased to US$7.50

Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)

Independent Director exercised options to buy US$230k worth of stock.

Consensus EPS estimates increase to -US$1.42

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021

Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited.

Athenex EPS beats by $0.13, beats on revenue

Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Athenex, Inc

Is Athenex (NASDAQ:ATNX) Weighed On By Its Debt Load?

Robbins LLP Reminds Shareholders that Athenex, Inc. is Being Sued for Misleading Shareholders

Chairman & CEO exercised options to buy US$98k worth of stock.

Insider recently sold US$1.9m worth of stock

Have Insiders Sold Athenex, Inc. (NASDAQ:ATNX) Shares Recently?

Analysts lower revenue estimates to US$115.2m

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts